IL7 and inflammatory bowel disease: In a mouse model of inflammatory bowel disease, EVs from WJ‐MSCs homed to colon tissues at 12 hours after injection and significantly relieved the severity of inflammatory bowel disease, with an effect similar to that of WJ‐MSCs used as controls, with a decrease of inflammatory cytokines in the colon and spleen and a modulation of IL‐7 expression in colonic macrophages.65